Clinical trial registry record

Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 30, 2013.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01148511
Last registry update
May 30, 2013
Status
Completed
Phase
Phase 4
Sponsor
Novartis Pharmaceuticals
Enrollment
99
Countries
Turkey (Türkiye)
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
99
Population
ALL · 50 Years
Duration
2010-02-01 to 2012-04-01
Intervention
Ranibizumab 0.5 mg
Comparator
Treat and Observe
Outcomes measured
Change in Best-Corrected Visual Acuity (logMAR) From Baseline to Month 12 — Baseline to Month 12; Change in Letter Count From Baseline to Month 12 — Baseline to Month 12; Letter Count From Baseline to Month 12 — Baseline to Month 12; Number of Visits — Baseline to Month 12; Follow-up Duration — Baseline to Month 12; Change in Central Retinal Thickness From Baseline to Month 12 — Baseline to Month 12; Quality of Life — Visits 2, 6, 9, 12, and 15 (up to 12 months)
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON